Lupin Gets USFDA Observations for Pithampur Plant

Sep 28, 2024 16:06

Lupin receives six observations from the USFDA following an inspection of its Pithampur plant in Madhya Pradesh. The company is addressing the observations and will respond within the stipulated timeframe.

New Delhi, Sep 28 (PTI) Drug firm Lupin on Saturday said the US health regulator has issued six observations after inspecting its Madhya Pradesh-based manufacturing facility.

The US Food and Drug Administration (USFDA) inspected the company's Pithampur Unit-1 API and finished product manufacturing facility from September 16 to September 27, 2024, Lupin said in a regulatory filing.

The inspection closed with three observations each on the API and finished product side, it added.

"We are addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe," the Mumbai-based drug maker said.

Source: PTI

MORE NEWS

Cathay Cargo Sees Growth in SE Asia, India...

Cathay Cargo director discusses Southeast Asia as a major market and exciting...

Stock Markets Fall on Global Weakness, FII...

Sensex and Nifty decline amid weak global cues, foreign fund outflows, and US-India...

Delhi Air Quality: Jahangirpuri AQI at 498...

Delhi air quality worsens, Jahangirpuri records AQI of 498, falling in the severe...

Rupee Hits Record Low: INR vs USD at 90.58

Rupee falls to a new all-time low of 90.58 against the US dollar amid trade deal...

DRI Seizes Red Sanders Worth Rs 6.26 Cr, 4...

DRI seizes 15 MT of red sanders worth Rs 6.26 crore in Delhi, arrests 4. Illegal export...

UAE Fund to Invest ₹1,000 Cr in Kerala Startups

UAE-based Feeder Fund to invest ₹1,000 crore in Kerala startups over 3 years. Boost...

ECL Aims for 58 MT Output, Mine Closures Planned

Eastern Coalfields Ltd (ECL) targets 58 MT output, plans closure of six underground...

India: Export Potential in Russia

300 Indian products have huge export potential in Russia. Engineering, pharma, agri,...

Gold & Silver Rally: Inflation Data in Focus

Gold and silver prices rally amid inflation data focus. Analysts eye central bank...

India Ranks 3rd in Global AI Vibrancy Index

India ranks 3rd in Stanford University's Global AI Vibrancy tool, surpassing advanced...

Lupin Gets USFDA Observations for Pithampur Plant

You May Like To Read

MORE NEWS